Abstract
Almost thirty percent of the protein targets currently under exploration and study constitute the protein kinases which have always attracted the pharmaceutical companies as they are easy targets for drug development. Although the kinases will remain major focus of oncology for many years to come in the development of anticancer drugs, the number of kinase inhibitors as therapeutic targets for the treatment of several other diseases which are undergoing clinical trials are exponentially increasing. In this review, we discuss very briefly the different types of protein kinases that have been used as targets for developing drugs for cancer, inflammation, autoimmune disease, heart disease and animal diseases.
Keywords: Cancer, inflammatory and autoimmune diseases, kinases, protein kinases.
Graphical Abstract
22
2
Related Articles
-
Identification of Expressed miRNAs in Human Rheumatoid Arthritis Using Computational Approach – Discovery of a New miR-7167 from Human
MicroRNA Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Challenge of Mesenchymal Stem Cells Against Diabetic Foot Ulcer
Current Stem Cell Research & Therapy Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets Update on ICOS: A Possible Target for Turning-Off Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) The Role of HLA Promoters in Autoimmunity
Current Pharmaceutical Design Imatinib Mesylate: An Innovation in Treatment of Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Target Therapies in Systemic Lupus Erythematosus: Current State of the Art
Mini-Reviews in Medicinal Chemistry Mechanism by which Regulatory Rheumatoid Factor Prevents Experimental Autoimmune Encephalomyelitis
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting T-Cell Adhesion Molecules for Drug Design
Current Pharmaceutical Design Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design Targeting of Th1-Associated Chemokine Receptors CXCR3 and CCR5 as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Recent Developments of 2–Substituted Analogs of 1,25(OH)<sub>2</sub>D<sub>3</sub>
Current Medicinal Chemistry Pathogenesis of Graves Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) The Effects of Dehydroepiandrosterone (DHEA) in the Treatment of Depression and Depressive Symptoms in Other Psychiatric and Medical Illnesses: A Systematic Review
Current Drug Targets Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine Nucleic Acid Enzymes as a Novel Generation of Anti-gene Agents
Current Molecular Medicine Anti-Inflammatory Approaches that Target the Chemokine Network
Recent Patents on Inflammation & Allergy Drug Discovery